DS-8201a Versus Ado Trastuzumab Emtansine for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane
Condition: Breast Cancer Interventions: Drug: Trastuzumab deruxtecan; Drug: Ado-trastuzumab emtansine Sponsors: Daiichi Sankyo, Inc.; Daiichi Sankyo Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials